Tasly Pharmaceutical Group Co., Ltd Stock price

Equities

600535

CNE000001C81

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
16 CNY -0.81% Intraday chart for Tasly Pharmaceutical Group Co., Ltd -6.32% -5.99%
Sales 2023 * 9.19B 1.27B Sales 2024 * 9.94B 1.38B Capitalization 23.81B 3.29B
Net income 2023 * 1.22B 168M Net income 2024 * 1.35B 187M EV / Sales 2023 * 2.39 x
Net cash position 2023 * 1.86B 257M Net cash position 2024 * 4.35B 601M EV / Sales 2024 * 1.96 x
P/E ratio 2023 *
19.8 x
P/E ratio 2024 *
17.8 x
Employees 9,183
Yield 2023 *
1.63%
Yield 2024 *
1.4%
Free-Float 49.13%
More Fundamentals * Assessed data
Dynamic Chart
Tasly Pharmaceutical Gets Nod to Trial Stem Cell Therapy MT
ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to S&P Global BMI Index CI
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to FTSE All-World Index CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tasly Pharmaceutical Gets Go Ahead to Launch Clinical Trial of Diabetic Kidney Drug MT
Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China CI
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug MT
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tasly Pharmaceutical Group Scraps Plan to Spin Off BioPharm Unit for Listing CI
Transcript : Mauna Kea Technologies SA, Tasly Pharmaceutical Group Co., Ltd - M&A Call
More news
1 day-0.81%
1 week-6.32%
Current month-5.16%
1 month-2.91%
3 months-6.16%
6 months+13.39%
Current year-5.99%
More quotes
1 week
15.97
Extreme 15.97
16.73
1 month
15.97
Extreme 15.97
17.71
Current year
13.02
Extreme 13.02
17.71
1 year
12.88
Extreme 12.88
18.00
3 years
9.20
Extreme 9.2
18.00
5 years
9.20
Extreme 9.2
25.23
10 years
9.20
Extreme 9.2
41.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 18-04-15
Director of Finance/CFO 47 18-07-08
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 60 07-08-16
Director/Board Member 72 05-09-08
Chairman 45 14-03-27
More insiders
Date Price Change Volume
24-03-27 16 -0.81% 10,753,000
24-03-26 16.13 0.00% 11,370,680
24-03-25 16.13 -1.77% 13,151,300
24-03-22 16.42 -1.85% 14,267,910
24-03-21 16.73 -2.05% 13,664,980

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
16 CNY
Average target price
14.92 CNY
Spread / Average Target
-6.75%
Consensus
  1. Stock
  2. Equities
  3. Stock Tasly Pharmaceutical Group Co., Ltd - Shanghai S.E.